Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma
Phase 2 Completed
49 enrolled 15 charts
Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase 2 Completed
77 enrolled 17 charts
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Phase 2 Completed
62 enrolled 15 charts
2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies
Phase 2 Completed
10 enrolled
High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Phase 2 Completed
64 enrolled 10 charts
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Phase 2 Completed
38 enrolled 11 charts
Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase 2 Completed
66 enrolled 12 charts
Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Phase 2 Completed
23 enrolled 10 charts
Blood Stem Cell Transplant With Low Dose Chemotherapy for Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN 0701)
Phase 2 Completed
65 enrolled 21 charts
Busulfan, Fludarabine Phosphate, and Anti-Thymocyte Globulin Followed By Donor Stem Cell Transplant and Azacitidine in Treating Patients With High-Risk Myelodysplastic Syndrome and Older Patients With Acute Myeloid Leukemia
Phase 2 Completed
68 enrolled 11 charts
Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
Phase 2 Completed
64 enrolled 7 charts
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
Phase 2 Completed
62 enrolled 15 charts
Azacitidine After Allo Blood And Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML)
Phase 2 Completed
24 enrolled 8 charts
Zevalin/BEAM/Rituximab vs BEAM/Rituximab With or Without Rituximab in Autologous Stem Cell Transplantation
Phase 2 Completed
30 enrolled 11 charts
Allogeneic Transplantation in Patients With Cutaneous T-Cell Lymphoma
Phase 2 Completed
33 enrolled 4 charts
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors
Phase 2 Completed
24 enrolled
High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma
Phase 2 Completed
75 enrolled 11 charts
Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)
Phase 2 Completed
20 enrolled 9 charts
Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies
Phase 2 Completed
73 enrolled 16 charts
Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide
Phase 2 Completed
176 enrolled 18 charts
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Phase 2 Completed
81 enrolled 8 charts
Bone Marrow Transplantation in Treating Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
49 enrolled
Busulfan Plus Clofarabine Followed by Allogeneic Hematopoietic Stem Cell Transplantation
Phase 2 Completed
120 enrolled 8 charts
Allogeneic Blood Stem Cell Transplantation and Adoptive Immunotherapy for Hodgkin's Disease
Phase 2 Completed
52 enrolled 7 charts
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
Phase 2 Completed
21 enrolled 13 charts
Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
47 enrolled 10 charts
Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma
Phase 2 Completed
100 enrolled 18 charts
Stem Cell Transplantation to Treat Systemic Mastocytosis
Phase 2 Completed
25 enrolled
Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies
Phase 2 Completed
68 enrolled 16 charts
Trial Of Double Umbilical Cord Blood Transplantation
Phase 2 Completed
20 enrolled 9 charts
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
Phase 2 Completed
147 enrolled 6 charts
Cord Blood Stem Cell Transplantation Study (COBLT)
Phase 2 Completed
Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia
Phase 2 Completed
56 enrolled 6 charts
Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL
Phase 2 Completed
20 enrolled 6 charts
Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases
Phase 2 Completed
12 enrolled 3 charts
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
Phase 2 Completed
32 enrolled 6 charts
Mini-Allogeneic Peripheral Blood Progenitor Cell Transplantation For Recurrent or Metastatic Breast Cancer
Phase 2 Completed
19 enrolled 8 charts
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
Phase 2 Completed
53 enrolled
Cellular Therapy With Cord Blood Cells
Phase 2 Completed
31 enrolled 6 charts
Tacrolimus, Sirolimus and Methotrexate as Graft Versus Host Disease Prophylaxis After Blood Stem Cell Transplantation
Phase 2 Completed
105 enrolled
Autologous Transplantation for Chronic Myelogenous Leukemia
Phase 2 Completed
24 enrolled
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
Phase 2 Completed
25 enrolled
Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies
Phase 2 Completed
17 enrolled